FLT3 (Y591_V592insVDFREYEYD)

FLT3 · Variant type: indel · HGVS: p.Y591_V592insVDFREYEYD

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Sunitinib	99.0%	0.9%	91.73
2	Gilteritinib	98.9%	1.1%	88.97
3	Pacritinib	98.8%	1.2%	88.64
4	Brigatinib	98.5%	1.5%	82.96
5	Quizartinib	98.0%	2.0%	99.50
6	Ponatinib	97.0%	3.0%	78.23
7	Selpercatinib	96.5%	3.5%	96.72
8	Defactinib	96.4%	3.6%	92.68
9	Fostamatinib	95.9%	4.1%	96.74
10	Pralsetinib	94.4%	5.6%	93.43
11	Nintedanib	93.4%	6.6%	90.23
12	Fedratinib	90.7%	9.3%	96.21
13	Avapritinib	89.6%	10.4%	97.73
14	Sorafenib	88.0%	12.0%	96.72
15	Entrectinib	86.5%	13.5%	93.69
16	Canertinib	84.3%	15.7%	96.49
17	Cabozantinib	83.5%	16.5%	92.73
18	Alectinib	81.4%	18.6%	95.49
19	Erlotinib	72.2%	27.8%	99.75
20	Rabusertib	68.6%	31.4%	98.74
21	Vandetanib	66.2%	33.8%	95.74
22	Ibrutinib	59.1%	40.9%	94.74
23	Tenalisib	58.6%	41.4%	97.98
24	Bosutinib	55.0%	45.0%	87.22
25	Osimertinib	53.1%	46.9%	97.24

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Sunitinib	99.0%	98.7%	+0.3%
Gilteritinib	98.9%	99.2%	-0.3%
Pacritinib	98.8%	93.6%	+5.3%
Brigatinib	98.5%	98.1%	+0.5%
Quizartinib	98.0%	97.9%	+0.1%
Ponatinib	97.0%	97.9%	-0.9%
Selpercatinib	96.5%	96.1%	+0.4%
Defactinib	96.4%	94.6%	+1.8%
Fostamatinib	95.9%	97.2%	-1.3%
Pralsetinib	94.4%	97.6%	-3.2%
Nintedanib	93.4%	95.2%	-1.9%
Fedratinib	90.7%	98.2%	-7.5%
Avapritinib	89.6%	88.6%	+1.0%
Sorafenib	88.0%	97.3%	-9.4%
Entrectinib	86.5%	96.1%	-9.6%
Canertinib	84.3%	86.3%	-2.0%
Cabozantinib	83.5%	95.0%	-11.5%
Alectinib	81.4%	84.5%	-3.1%
Erlotinib	72.2%	—	—
Rabusertib	68.6%	—	—
Vandetanib	66.2%	—	—
Ibrutinib	59.1%	88.1%	-29.0%
Tenalisib	58.6%	—	—
Bosutinib	55.0%	—	—
Osimertinib	53.1%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 27.6ms